Results 251 to 260 of about 92,046 (305)
Some of the next articles are maybe not open access.
Urologia Journal, 2016
Transitional cell carcinoma (TCC) is the tumor that most frequently affects the urinary tract. The most common location is in the bladder; the diagnosis, as the follow-up, is based on urine cytology, endoscopic, and radiological examinations. Urinary cytology is an important non invasive tool used in the diagnosis and follow-up of patients with TCC. A
Ragonese, Mauro +9 more
openaire +4 more sources
Transitional cell carcinoma (TCC) is the tumor that most frequently affects the urinary tract. The most common location is in the bladder; the diagnosis, as the follow-up, is based on urine cytology, endoscopic, and radiological examinations. Urinary cytology is an important non invasive tool used in the diagnosis and follow-up of patients with TCC. A
Ragonese, Mauro +9 more
openaire +4 more sources
Durvalumab in urothelial cancers
Expert Review of Anticancer Therapy, 2018Urothelial bladder cancer is one of the most predominant malignancies worldwide with a poor prognosis when presented at an advanced or metastatic stage. Improving the therapeutic landscape in this setting has been an unmet medical need. Palliative cisplatin-based chemotherapy is currently the standard of care in first line therapies, but many patients ...
Pernelle, Lavaud +3 more
openaire +2 more sources
European Journal of Radiology, 2018
While urothelial carcinoma is a very common tumor, involvement of the upper tract is relatively uncommon. Consequently, there are no consensus imaging recommendations for upper tract disease. CT urography is the dominant imaging modality for the upper tract, but despite its excellent performance characteristics and being widely accepted as standard of ...
Adam, Froemming +3 more
openaire +2 more sources
While urothelial carcinoma is a very common tumor, involvement of the upper tract is relatively uncommon. Consequently, there are no consensus imaging recommendations for upper tract disease. CT urography is the dominant imaging modality for the upper tract, but despite its excellent performance characteristics and being widely accepted as standard of ...
Adam, Froemming +3 more
openaire +2 more sources
Systemic Chemotherapy for Urothelial Cancer
Clinical Genitourinary Cancer, 2006Although metastatic transitional cell carcinoma of the bladder and urothelium commonly responds to first-line chemotherapy, eventual progression is nearly universal. Current salvage therapy for progressive disease after first-line chemotherapy is ineffective, and such patients are candidates for clinical trials.
Guru, Sonpavde +2 more
openaire +2 more sources
Urothelial cancers after renal transplantation
International Urology and Nephrology, 2011After solid organ transplantation, risk of cancer varies significantly based on cancer type. In this study, we determine the incidence of urothelial cancers (bladder and kidney) after renal transplantation from a single high-volume transplantation institution. In addition, we analyze the risk factors and review outcomes from the patients.We performed a
Jared, Cox, Janet L, Colli
openaire +2 more sources
Emerging therapies for urothelial cancer
Cancer Treatment Reviews, 2012Urothelial carcinoma is one of the leading causes of death in Europe and the United States. Despite its chemosensitivity, median overall survival for advanced disease is still nearly 1 year. Most second-line chemotherapeutic agents tested have been disappointing. Thus, new treatment strategies are clearly needed.
César, Serrano +8 more
openaire +2 more sources
Evolving systemic management of urothelial cancers
Current Opinion in Oncology, 2023Purpose of review Bladder cancer is the 12th most common cancer worldwide. Historically, the systemic management of urothelial carcinoma has been confined to platinum-based chemotherapy. In this review, we discuss the evolving landscape of systemic treatment for urothelial carcinoma.
Wei Shen, Tan +5 more
openaire +2 more sources
Diagnostic Imaging of Urothelial Cancer
Urologic Clinics of North America, 1984Technologic advances in diagnostic imaging offer new ways to evaluate urothelial tumors. Computed tomography, ultrasound, and magnetic resonance imaging each have potential to provide information previously unavailable without surgical intervention.
E J, Lantz, R R, Hattery
openaire +2 more sources
New Developments in Urothelial Cancer
American Society of Clinical Oncology Educational Book, 2012Overview: Urothelial cancer is among the most chemotherapy-sensitive neoplasms of all the solid tumors. However, for the majority of patients with advanced disease, response durations with conventional treatment are relatively short. Second-line systemic treatment regimens are associated with modest response rates and poor outcomes.
openaire +2 more sources